Medical immunology: Two-way bridge connecting bench and bedside

Immunology Letters

Volumn 162, Issue 2, 2014, Pages 127-133

  Rijkers, Ger T ^a,b   Damoiseaux, Jan G M C ^c   Hooijkaas, Herbert ^d  

^a University College Roosevelt   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti cyclic citrullinated peptide; Immunodeficiency; Laboratory medicine; Medical immunology; Rheumatoid arthritis; X linked agammaglobulinemia

Indexed keywords

ANTIPERINUCLEAR FACTOR; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN M ANTIBODY; RHEUMATOID FACTOR;

ALLERGY; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; HISTOCOMPATIBILITY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNOLOGIST; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISEASE; MEDICAL EDUCATION; MEDICAL IMMUNOLOGY; NETHERLANDS; NONHUMAN; PREDICTIVE VALUE; REVIEW; RHEUMATOID ARTHRITIS; TRANSFUSION; X LINKED AGAMMAGLOBULINEMIA; ANIMAL; IMMUNE SYSTEM DISEASES; LYMPHOPROLIFERATIVE DISORDERS; PROCEDURES; TRANSLATIONAL RESEARCH; TRENDS;

ALLERGY AND IMMUNOLOGY; ANIMALS; HUMANS; IMMUNE SYSTEM DISEASES; LYMPHOPROLIFERATIVE DISORDERS; NETHERLANDS; TRANSLATIONAL MEDICAL RESEARCH; TRANSPLANTATION IMMUNOLOGY;

EID: 84913559595     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.10.016     Document Type: Review

References (59)

1. Van Rood J., Claas F., Brand A., Tilanus M., van Kooten C. Transplantation immunology. Immunol Lett 2014, 162:145-149.
2. Gmelig-Meyling F.H.J., Hooijkaas H. Medical immunology in the Netherlands. Growing up in Pediatric Immunology 2002, 177-187. Utrecht. G.J. Heijnen, A. Kavelaars, G.T. Rijkers (Eds.).
3. Fahey J.L. Clinical Immunology Society: the early years 1984-1989. I. An introduction. J Clin Immunol 2011, 31:533-536.
4. Bene M.C. State-of-the-art of clinical immunology in Europe. Immunol Lett 2000, 71:191-201.
5. Bene M.C., Stockinger H., Capel P.J.A., Chapel H., Knapp W. Clinical Immunology: a unified vision for Europe. Immunol Today 2000, 21:210-211.
6. Choremi-Papadopoulou H., Faure G.C., Grunmet N., Malenica B., Misbah S.A., Theodorsson E., et al. Position statement: training programme in immunology of the European board of UEMS Medical Pathology. Immunol Lett 2005, 96:305-310.
7. Cohen Tervaert J.W., Kallenberg C., Ten Berge I. Clinical immunology. Immunol Lett 2014, 162:134-140.
8. CMI-training requirements-Dutch Society for Immunology, [assessed 08.08.14]. http://www.dutchsocietyimmunology.nl/.
9. Choremi-Papalopoulou E., Fauze G.C., Malenika B., Misbah S.A., Zablinger G.J. Position statement: assessment strategy for implementation of the immunology curriculum of the European board of UEMS medical pathology. Immunol Lett 2009, 59-64.
10. Section of Laboratory Medicine/Medical Biopathology Recommended standards for training specialists in Laboratory Medicine/Medical Biopathology 2012, May, [assessed 08.08.14]. http://www.uems-s%20mb.org/.
11. Joint guidelines and rules for organizing the: EFLM-UEMS, European joint congress in laboratory medicine, entitled 'Laboratory Medicine at the clinical interface' 2014, February, www.uems-smb.org [assessed 08.08.14].
12. Memorandum of understanding between the European federation of Clinical Chemistry and Laboratory Medicine (EFLM) and the U.E.M.S. section of Laboratory Medicine 2014, March, www.uems-smb.org [assessed 08.08.14].
13. Oosterhuis W.P., Zerah S. Laboratory medicine in The European Union. Clin Chem Lab Med 2014, [Epub ahead of print].
14. EFML position Statement Our profession now has a European name: specialist in laboratory medicine. Biochem Med 2012, 22:272-273.
15. Fahey J.L. Clinical laboratory immunology: the Future. Clin Diagn Lab Immun 1999, 6:291-292.
16. de Vries E. Clinical Working Party of the European Society for Immunodeficiencies (ESID). Patient-centered screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists. Clin Exp Immunol 2006, 145:204-214.
17. de Vries E. European Society for Immunodeficiencies (ESID) members. Patient-centered screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. Clin Exp Immunol 2012, 167:108-119.
18. Houten S.M., Kuis W., Duran M., de Koning T.J., van Royen-Kerkhof A., Romeijn G.J., et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999, 22:175-177.
19. Drenth J.P., Cuisset L., Grateau G., Vasseur C., van de Velde-Visser S.D., de Jong J.G., et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999, 22:178-181.
20. Roos D., de Boer M. Molecular diagnosis of chronic granulomatous disease. Clin Exp Immunol 2014, 175:139-149.
21. Al-Herz W., Bousfiha A., Casanova J.L., Chatila T., Conley M.E., Cunningham-Rundles C., et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2014, 5:162.
22. Conley M.E., Casanova J.L. Discovery of single-gene inborn errors of immunity by next generation sequencing. Curr Opin Immunol 2014, 30C:17-23.
23. Bruton O.C. Agammaglobulinemia. Pediatrics 1952, 9:722-728.
24. Conley M.E., Cooper M.D. Genetic basis of abnormal B cell development. Curr Opin Immunol 1998, 10:399-406.
25. Tsukada S., Saffran D.C., Rawlings D.J., Parolini O., Allen R.C., Klisak I., et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993, 72:279-290.
26. Vetrie D., Vorechovský I., Sideras P., Holland J., Davies A., Flinter F., et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993, 361:226-233.
27. Väliaho J., Smith C.I., Vihinen M. BTKbase: the mutation database for X-Linked agammaglobulinemia. Hum Mutat 2006, 27:1209-1217.
28. [assessed 05.08.14]. http://structure.bmc.lu.se/idbase/.
29. Hendriks R.W., Bredius R.G., Pike-Overzet K., Staal F.J. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opin Ther Targets 2011, 15:1003-1021.
30. van der Burg M., van Zelm M.C., Driessen G.J., van Dongen J.J. New frontiers of primary antibody deficiencies. Cell Mol Life Sci 2012, 69:59-73.
31. van Zelm M.C., Reisli I., van der Burg M., Castaño D., van Noesel C.J., van Tol M.J., et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006, 354:1901-1912.
32. Kuijpers T.W., Bende R.J., Baars P.A., Grummels A., Derks I.A., Dolman K.M., et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010, 120:214-222.
33. Thiel J., Kimmig L., Salzer U., Grudzien M., Lebrecht D., Hagena T., et al. Genetic CD21 deficiency is associated with hypogammaglobulinemia. J Allergy Clin Immunol 2012, 129:801-810.
34. Sanders L.A., Rijkers G.T., Kuis W., Tenbergen-Meekes A.J., de Graeff-Meeder B.R., Hiemstra I., et al. Defective antipneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections. J Allergy Clin Immunol 1993, 91:110-119.
35. Rijkers G.T., Sanders L.A., Zegers B.J. Anti-capsular polysaccharide antibody deficiency states. Immunodeficiency 1993, 5:1-21.
36. Notarangelo L., Casanova J.L., Conley M.H., Chapel H., Fischer A., Puck J., et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee meeting in Budapest, 2005. J Allergy Clin Immunol 2006, 117:883-896.
37. Wood P.M., Mayne A., Joyce H., Smith C.I., Granoff D.M., Kumararatne D.S. A mutation in Bruton's tyrosine kinase as a cause of selective anti-polysaccharide antibody deficiency. J Pediatr 2001, 139:148-151.
38. Ku C.L., Picard C., Erdös M., Jeurissen A., Bustamante J., Puel A., et al. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J Med Genet 2007, 44:16-23.
39. Yel L. Selective IgA deficiency. J Clin Immunol 2010, 30:10-16.
40. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep corpuscles. Acta Pathol Microbiol Scand 1940, 1:172-188.
41. Arnett F.D., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
42. Nienhuis R.L.F., Mandema E. A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann Rheum Dis 1964, 23:302-305.
43. Sondag-Tschroots I.R.J.M., Aaij C., Smit J.W., Feltkamp T.E.W. The antiperinuclear factor. 1. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. Ann Rheum Dis 1979, 38:248-251.
44. Young B.J.J., Mallya R.K., Leslie R.D.G., Clark C.J.M., Hamblin T.J. Anti-keratin antibodies in rheumatoid arthritis. Brit Med J 1979, 2:97-99.
45. Sebbag M., Simon M., Vincent C., Masson-Bessiere C., Girbal E., Durieux J.J., et al. The antiperinuclear factor and the so-calles "antikeratin antibodies" are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995, 95:2672-2679.
46. Schellekens G.A., De Jong B.A.W., Van den Hoogen F.H.J., Van de Putte L.B.A., Van Venrooij Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101:273-281.
47. Girbal-Neuhauser E., Durieux J.J., Arnaud M., Dalbon P., Sebbag M., Vincent C., et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deamination of arginine residues. J Immunol 1999, 162:585-594.
48. Van Venrooij W., Van Beers J.J.B.C., Pruijn G.J.M. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011, 7:391-398.
49. Bizzaro N., Tonutti E., Tozzoli R., Villalta D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007, 53:1527-1533.
50. Rantapää-Dahlqvist S., De Jong B.A., Berglin E., Hallmans G., Wadell G., Stenlund H., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749.
51. Nielen M.M., Van Schaardenburg D., Reesink H.W., Van de Stadt R.J., Van der Horst-Bruinsma I.E., De Koining M.H., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-386.
52. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
53. Damoiseaux J., Cohen Tervaert J.W., Derksen R., Hamann D., Hooijkaas H., Klasen I., et al. Autoantibody standardization in the Netherlands. Ann NY Acad Sci 2009, 1173:10-14.
54. Bizarro N., Pregnolato F., Van Boekel M.A.M., Villalta D., Tozzoli R., Tonutti E., et al. Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies. Ann Rheum Dis 2012, 71:1388-1392.
55. Damoiseaux J. Autoantibodies in the grocery shop: does quantity matter?. Immunol Res 2013, 56:413-419.
56. Bossuyt X., Coenen D., Fieuws S., Verschueren P., Westhovens R., Blanckaert N. Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor. Ann Rheum Dis 2009, 68:287-289.
57. Shi J., Van Veelen P.A., Mahler M., Janssen G.M., Drijfhout J.W., Huizinga T.W., et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev 2014, 13:225-230.
58. McNutt M. Cancer immunotherapy. Science 2013, 342:1417.
59. Stoop J.W. Immune responsiveness and recurrent respiratory tract infections in young children 1965, Utrecht University, [Thesis].